Heron Therapeutics/HRTX

$2.84

-3.07%
-
1D1W1MYTD1YMAX

About Heron Therapeutics

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Ticker

HRTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Craig Collard

Employees

126

Headquarters

San diego, United States

HRTX Metrics

BasicAdvanced
$443.47M
Market cap
-
P/E ratio
-$0.87
EPS
1.67
Beta
-
Dividend rate
$443.47M
1.66875
$3.22
$0.50
2.64M
2.369
1.841
-46.7%
-71%
3.491
17.99%
49.39%
12.75%

What the Analysts think about HRTX

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
146.48% upside
High $9.00
Low $5.00
$2.84
Current price
$7.00
Average price target

HRTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-31.28% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$34.2M
8.92%
Net income
$-10.7M
-57.2%
Profit margin
-31.28%
-60.71%

HRTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 57.23%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.27
-$0.35
-$0.17
-$0.07
-
Expected
-$0.20
-$0.23
-$0.29
-$0.16
-$0.09
Surprise
33%
49.96%
-41.88%
-57.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Heron Therapeutics stock?

Heron Therapeutics (HRTX) has a market cap of $443.47M as of April 17, 2024.

What is the P/E ratio for Heron Therapeutics stock?

The price to earnings (P/E) ratio for Heron Therapeutics (HRTX) stock is 0 as of April 17, 2024.

Does Heron Therapeutics stock pay dividends?

No, Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Heron Therapeutics dividend payment date?

Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Heron Therapeutics?

Heron Therapeutics (HRTX) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Heron Therapeutics stock price target?

The target price for Heron Therapeutics (HRTX) stock is $7, which is 151.8% above the current price of $2.78. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Heron Therapeutics stock

Buy or sell Heron Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing